Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA249456
Max Phase: Preclinical
Molecular Formula: C22H22N4O2
Molecular Weight: 374.44
Molecule Type: Small molecule
Associated Items:
ID: ALA249456
Max Phase: Preclinical
Molecular Formula: C22H22N4O2
Molecular Weight: 374.44
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 4,4'-(1,3-Phenylenebis(Methylene))Bis(Oxy)Dibenzimidamide
Synonyms from Alternative Forms(1):
Canonical SMILES: N=C(N)c1ccc(OCc2cccc(COc3ccc(C(=N)N)cc3)c2)cc1
Standard InChI: InChI=1S/C22H22N4O2/c23-21(24)17-4-8-19(9-5-17)27-13-15-2-1-3-16(12-15)14-28-20-10-6-18(7-11-20)22(25)26/h1-12H,13-14H2,(H3,23,24)(H3,25,26)
Standard InChI Key: OHCPXJHKRQZPCL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 374.44 | Molecular Weight (Monoisotopic): 374.1743 | AlogP: 3.41 | #Rotatable Bonds: 8 |
Polar Surface Area: 118.20 | Molecular Species: BASE | HBA: 4 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 12.12 | CX LogP: 2.95 | CX LogD: -1.87 |
Aromatic Rings: 3 | Heavy Atoms: 28 | QED Weighted: 0.36 | Np Likeness Score: -0.24 |
1. Cruz-Monteagudo M, Borges F, Perez González M, Cordeiro MN.. (2007) Computational modeling tools for the design of potent antimalarial bisbenzamidines: overcoming the antimalarial potential of pentamidine., 15 (15): [PMID:17533134] [10.1016/j.bmc.2007.05.034] |
2. Patrick DA, Bakunov SA, Bakunova SM, Kumar EV, Chen H, Jones SK, Wenzler T, Barzcz T, Werbovetz KA, Brun R, Tidwell RR.. (2009) Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes., 44 (9): [PMID:19409677] [10.1016/j.ejmech.2009.03.014] |
3. Vanden Eynde JJ, Mayence A, Johnson MT, Huang TL, Collins MS, Rebholz S, Walzer PD, Cushion MT, Donkor IO. (2005) Antitumor and Anti-Pneumocystis Carinii Activities of Novel Bisbenzamidines, 14 (3): [10.1007/s00044-005-0130-2] |
4. Berger ML, Maciejewska D, Vanden Eynde JJ, Mottamal M, Żabiński J, Kaźmierczak P, Rezler M, Jarak I, Piantanida I, Karminski-Zamola G, Mayence A, Rebernik P, Kumar A, Ismail MA, Boykin DW, Huang TL.. (2015) Pentamidine analogs as inhibitors of [(3)H]MK-801 and [(3)H]ifenprodil binding to rat brain NMDA receptors., 23 (15): [PMID:26117647] [10.1016/j.bmc.2015.06.012] |
5. Beckmann AM, Gilberg E, Gattner S, Huang TL, Vanden Eynde JJ, Mayence A, Bajorath J, Stirnberg M, Gütschow M.. (2016) Evaluation of bisbenzamidines as inhibitors for matriptase-2., 26 (15): [PMID:27287367] [10.1016/j.bmcl.2016.05.071] |
Source(1):